Biostar Pharmaceuticals Stock Performance
| BSPM Stock | USD 0.0001 0.00 0.00% |
The firm shows a Beta (market volatility) of 0.0, which signifies not very significant fluctuations relative to the market. the returns on MARKET and Biostar Pharmaceuticals are completely uncorrelated.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Biostar Pharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of very healthy basic indicators, Biostar Pharmaceuticals is not utilizing all of its potentials. The current stock price disarray, may contribute to short-term losses for the investors. ...more
Biostar |
Biostar Pharmaceuticals Relative Risk vs. Return Landscape
If you would invest 0.01 in Biostar Pharmaceuticals on October 13, 2025 and sell it today you would earn a total of 0.00 from holding Biostar Pharmaceuticals or generate 0.0% return on investment over 90 days. Biostar Pharmaceuticals is currently does not generate positive expected returns and assumes 0.0% risk (volatility on return distribution) over the 90 days horizon. In different words, 0% of pink sheets are less volatile than Biostar, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Biostar Pharmaceuticals Market Risk Analysis
Today, many novice investors tend to focus exclusively on investment returns with little concern for Biostar Pharmaceuticals' investment risk. Standard deviation is the most common way to measure market volatility of pink sheets, such as Biostar Pharmaceuticals, and traders can use it to determine the average amount a Biostar Pharmaceuticals' price has deviated from the expected return over a period of time. It is calculated by determining the expected price for the established period and then subtracting this figure from each price point. The differences are then squared, summed, and averaged to produce the variance.
Sharpe Ratio = 0.0
| High Returns | Best Equity | |||
| Good Returns | ||||
| Average Returns | ||||
| Small Returns | ||||
| Cash | Small Risk | Average Risk | High Risk | Huge Risk |
| BSPM |
Based on monthly moving average Biostar Pharmaceuticals is not performing at its full potential. However, if added to a well diversified portfolio the total return can be enhanced and market risk can be reduced. You can increase risk-adjusted return of Biostar Pharmaceuticals by adding Biostar Pharmaceuticals to a well-diversified portfolio.
Biostar Pharmaceuticals Fundamentals Growth
Biostar Pink Sheet prices reflect investors' perceptions of the future prospects and financial health of Biostar Pharmaceuticals, and Biostar Pharmaceuticals fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Biostar Pink Sheet performance.
| Return On Equity | 0.0266 | |||
| Return On Asset | 0.0425 | |||
| Profit Margin | 2.94 % | |||
| Operating Margin | 8.76 % | |||
| Current Valuation | 316.46 K | |||
| Shares Outstanding | 2.64 M | |||
| Price To Book | 0.01 X | |||
| Price To Sales | 0.0001 X | |||
| Revenue | 317.79 K | |||
| EBITDA | (1.7 M) | |||
| Cash And Equivalents | 364.97 K | |||
| Cash Per Share | 0.14 X | |||
| Debt To Equity | 0.07 % | |||
| Book Value Per Share | 13.71 X | |||
| Cash Flow From Operations | 4.91 M | |||
| Earnings Per Share | 0.06 X | |||
| Total Asset | 42.5 M | |||
| Retained Earnings | 3.16 M | |||
| Current Asset | 16.17 M | |||
| Current Liabilities | 7.1 M | |||
About Biostar Pharmaceuticals Performance
By examining Biostar Pharmaceuticals' fundamental ratios, stakeholders can obtain critical insights into Biostar Pharmaceuticals' financial health, operational efficiency, and overall profitability. These insights assist in making well-informed investment and management decisions. For example, a high Return on Assets and Return on Equity would indicate that Biostar Pharmaceuticals is effectively utilizing its assets and equity to generate significant profits, enhancing its appeal to investors. On the other hand, low ROA and ROE values could reveal issues in asset and equity management, highlighting the need for operational improvements.
Biostar Pharmaceuticals, Inc. develops, manufactures, and markets over-the-counter and prescription pharmaceutical products for various diseases and conditions in the Peoples Republic of China. The company was incorporated in 2007 and is headquartered in Xianyang, the Peoples Republic of China. Biostar Pharmaceuticals operates under Pharmaceuticals And Biosciences classification in the United States and is traded on OTC Exchange. It employs 200 people.Things to note about Biostar Pharmaceuticals performance evaluation
Checking the ongoing alerts about Biostar Pharmaceuticals for important developments is a great way to find new opportunities for your next move. Pink Sheet alerts and notifications screener for Biostar Pharmaceuticals help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Biostar Pharmaceuticals generated a negative expected return over the last 90 days | |
| Biostar Pharmaceuticals has some characteristics of a very speculative penny stock | |
| The company has a current ratio of 0.19, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Biostar Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Biostar Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Biostar Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Biostar to invest in growth at high rates of return. When we think about Biostar Pharmaceuticals' use of debt, we should always consider it together with cash and equity. | |
| Biostar Pharmaceuticals reported the previous year's revenue of 317.79 K. Net Loss for the year was (5.7 M) with profit before overhead, payroll, taxes, and interest of 915.17 K. |
- Analyzing Biostar Pharmaceuticals' financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Biostar Pharmaceuticals' stock is overvalued or undervalued compared to its peers.
- Examining Biostar Pharmaceuticals' industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Biostar Pharmaceuticals' management team can have a significant impact on its success or failure. Reviewing the track record and experience of Biostar Pharmaceuticals' management team can help you assess the Company's leadership.
- Pay attention to analyst opinions and ratings of Biostar Pharmaceuticals' pink sheet. These opinions can provide insight into Biostar Pharmaceuticals' potential for growth and whether the stock is currently undervalued or overvalued.
Other Information on Investing in Biostar Pink Sheet
Biostar Pharmaceuticals financial ratios help investors to determine whether Biostar Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Biostar with respect to the benefits of owning Biostar Pharmaceuticals security.